QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:VINC

Vincerx Pharma - VINC Stock Forecast, Price & News

$1.31
0.00 (0.00%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.31
▼
$1.40
50-Day Range
$0.64
▼
$1.51
52-Week Range
$0.63
▼
$7.14
Volume
26,202 shs
Average Volume
100,213 shs
Market Capitalization
$27.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Vincerx Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
666.3% Upside
$10.00 Price Target
Short Interest
Healthy
3.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$55,983 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.89) to ($1.45) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

83rd out of 1,027 stocks

Pharmaceutical Preparations Industry

31st out of 500 stocks

See Top Rated MarketRank™ Stocks Here
VINC stock logo

About Vincerx Pharma (NASDAQ:VINC) Stock

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Receive VINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.

VINC Stock News Headlines

February 6, 2023 | finance.yahoo.com
Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference
December 15, 2022 | msn.com
Peering Into Vincerx Pharma's Recent Short Interest
February 6, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
December 13, 2022 | finance.yahoo.com
Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236
December 11, 2022 | finance.yahoo.com
Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022
November 10, 2022 | finance.yahoo.com
Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 3, 2022 | finance.yahoo.com
Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022
September 22, 2022 | nasdaq.com
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely
February 6, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
September 20, 2022 | finance.yahoo.com
Vincerx Pharma, Inc. (VINC)
August 12, 2022 | markets.businessinsider.com
5 Analysts Have This to Say About Vincerx Pharma
August 11, 2022 | finance.yahoo.com
We Think Vincerx Pharma (NASDAQ:VINC) Needs To Drive Business Growth Carefully
August 11, 2022 | finance.yahoo.com
Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
July 1, 2022 | finance.yahoo.com
Insider Buying: The Vincerx Pharma, Inc. (NASDAQ:VINC) Founder Just Bought 2.5% More Shares
June 10, 2022 | finance.yahoo.com
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress
June 7, 2022 | finance.yahoo.com
Analysts Cuts Price Target On This Small Cap But Remain Bullish
June 7, 2022 | markets.businessinsider.com
7 Analysts Have This to Say About Vincerx Pharma
June 7, 2022 | finance.yahoo.com
Small Cap Biotech Vincerx Cuts Third Of Staff
June 6, 2022 | seekingalpha.com
Vincerx Pharma to cut workforce by 33%, prioritize resources on ongoing trials
June 6, 2022 | finance.yahoo.com
Vincerx Pharma Provides Key Strategic Update
June 6, 2022 | finance.yahoo.com
Vincerx Pharma, Inc. (NASDAQ:VINC) up 10%, but insiders are still down 85% after purchasing US$806k of stock last year
May 25, 2022 | uk.investing.com
Stocks That Hit 52-Week Lows On Tuesday By Benzinga - Investing.com UK
May 19, 2022 | nasdaq.com
Buying Power of Bitcoin vs. Vincerx Pharma at New 52-Week High
May 13, 2022 | benzinga.com
Chardan Capital Maintains Buy on Vincerx Pharma, Lowers Price Target to $11 - Benzinga - Benzinga
May 13, 2022 | globenewswire.com
Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update - GlobeNewswire
April 11, 2022 | finance.yahoo.com
Vincerx Pharma Highlights VIP152 Preclinical, Clinical Data In Gynecological Cancers
March 30, 2022 | seekingalpha.com
Vincerx Pharma GAAP EPS of -$0.31
See More Headlines
Receive VINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.

VINC Company Calendar

Last Earnings
11/10/2022
Today
2/06/2023
Next Earnings (Estimated)
4/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VINC
CUSIP
N/A
CIK
1796129
Web
vincerapharma.com
Phone
650-800-6676
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+663.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-39,310,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-85.86%
Return on Assets
-72.79%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.76
Quick Ratio
6.76

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.76 per share
Price / Book
0.28

Miscellaneous

Outstanding Shares
21,190,000
Free Float
16,189,000
Market Cap
$27.76 million
Optionable
Not Optionable
Beta
0.48

Key Executives

  • Dr. Ahmed M. Hamdy M.D. (Age 57)
    Founder, Chairman & CEO
    Comp: $614.91k
  • Mr. Tom C. Thomas J.D.Mr. Tom C. Thomas J.D. (Age 63)
    Founder, Gen. Counsel & Chief Legal Officer
    Comp: $444.14k
  • Dr. Raquel E. Izumi Ph.D. (Age 52)
    Founder, Pres, COO, Sec. & Director
  • Dr. John C. Byrd M.D.
    Founder & Chairman of Scientific Advisory Board
  • Mr. Alexander A. Seelenberger M.B.A.Mr. Alexander A. Seelenberger M.B.A. (Age 43)
    MBA, Chief Financial Officer
  • Dr. Hans-Georg Lerchen Ph.D.
    Chief Scientific Officer
  • Ms. Melissa Merrick SPHR
    Sr. Director of People & Culture
  • Dr. David Nganele M.B.A.
    Ph.D., Head of Early Devel.
  • Dr. Beatrix Stelte-Ludwig Ph.D.
    Exec. Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VINC Stock - Frequently Asked Questions

Should I buy or sell Vincerx Pharma stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VINC shares.
View VINC analyst ratings or view top-rated stocks.

What is Vincerx Pharma's stock price forecast for 2023?

5 Wall Street research analysts have issued twelve-month target prices for Vincerx Pharma's stock. Their VINC share price forecasts range from $3.00 to $28.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 663.4% from the stock's current price.
View analysts price targets for VINC or view top-rated stocks among Wall Street analysts.

How have VINC shares performed in 2023?

Vincerx Pharma's stock was trading at $1.02 at the start of the year. Since then, VINC shares have increased by 28.4% and is now trading at $1.31.
View the best growth stocks for 2023 here.

When is Vincerx Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our VINC earnings forecast.

How were Vincerx Pharma's earnings last quarter?

Vincerx Pharma, Inc. (NASDAQ:VINC) issued its quarterly earnings data on Thursday, November, 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.80).

What is Vincerx Pharma's stock symbol?

Vincerx Pharma trades on the NASDAQ under the ticker symbol "VINC."

Who are Vincerx Pharma's major shareholders?

Vincerx Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Sage Rhino Capital LLC (7.96%). Insiders that own company stock include Ahmed Md Hamdy, Alexander A Seelenberger, Andrew I Mcdonald, Christopher P Lowe, Laura I Bushnell, Raquel E Izumi and Tom C Thomas.
View institutional ownership trends.

How do I buy shares of Vincerx Pharma?

Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vincerx Pharma's stock price today?

One share of VINC stock can currently be purchased for approximately $1.31.

How much money does Vincerx Pharma make?

Vincerx Pharma (NASDAQ:VINC) has a market capitalization of $27.76 million. The company earns $-39,310,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

How can I contact Vincerx Pharma?

Vincerx Pharma's mailing address is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. The official website for the company is vincerapharma.com. The company can be reached via phone at 650-800-6676.

This page (NASDAQ:VINC) was last updated on 2/6/2023 by MarketBeat.com Staff